Skip to main content

Antioxidant Supplements, Genetics and Chemotherapy Outcomes

Buy Article:

$63.00 plus tax (Refund Policy)

Cancer patients report widespread use of antioxidant supplements during chemotherapy, despite recommendations by the American Institute for Cancer Research and others that supplements should not be used during treatment. These guidelines are based upon the fact that numerous chemotherapeutic agents, as well as radiation therapy, exert their cytotoxic effects by generation of reactive oxygen species (ROS), which cause massive damage to DNA and proteins and trigger apoptosis, resulting in tumor and normal cell death. Thus, there is the concern that antioxidants may block the ROS-generated effects of therapy on tumor cells. There are no data based on sound epidemiological or clinical studies to support this hypothesis, however. In fact, some experimental studies have shown that antioxidants may potentiate the effects of chemotherapeutic drugs, while also lessening treatment-related toxicities. In this report, we review the literature regarding chemotherapy and radiation therapy as sources of oxidative stress, and present the current data regarding effects of antioxidant supplement use on normal and cancer cells. The role of antioxidant supplements, as well as the role of genetic variants in oxidative stress genes, in relation to cancer treatment toxicities and survival are discussed.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: antioxidant supplements; chemotherapy; polymorphisms; reactive oxygen species; survival; toxicity

Document Type: Review Article

Affiliations: Department of Epidemiology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263,USA.

Publication date: 2005-11-01

More about this publication?
  • Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more